Home Haemodialysis in Wales An Evaluation of Nutritional Needs Harriet Williams Clinical Dietitian - Renal Lead, BCU.

Slides:



Advertisements
Similar presentations
UK Renal Registry 13th Annual Report Figure 12.1: Median height z-scores for transplant patients in 2009.
Advertisements

Hyperphosphataemia in chronic kidney disease Clinical case scenarios
What Do I want ??? Sudhakar Venturi ST4.
Chronic Kidney Disease Manju Sood GPST3. What is CKD? Chronic renal failure is the progressive loss of nephrons resulting in permanent compromise of renal.
Nutrition Therapy and Dialysis Melinda S. Leone, MS, RD St. Joseph's Regional Medical Center Division of Nephrology Paterson, NJ 07503
UK Renal Registry 16th Annual Report Figure Data completeness for key variables, stratified by first modality HD = haemodialysis; PD = peritoneal.
A Workshop Facilitated by Glenda M. Payne, RN, MS, CNN ESRD Technical Advisor, CMS Regions 4 & 6 Dallas, TX.
Nutrition Care Process (NCP)
The future of haemodialysis in the UK RCP advanced medicine 2013 Cormac Breen Consultant Nephrologist Guy's and St Thomas' Hospitals London.
UK Renal Registry 15th Annual Report Figure One year death rate per 1,000 patient years by UK country and age group for prevalent dialysis.
West Midlands Guidelines for managing CKD Mineral and Bone Disorders in Haemodialysis Patients
Phosphate Control - secrets of ‘good’ units Hugh Cairns on behalf of Tyrone Hospital, Royal Berkshire Hospital and King’s.
Reference Avram MM, et al. Hemoglobin predicts long-term survival in dialysis patients: a 15-year single-center longitudinal study and a correlation trend.
Dialysis Facility Compare Valarie Ashby Co-Managing Director UM-KECC.
UK Renal Registry 16th Annual Report Figure 8.1. Trend in 1 year after 90 day incident patient survival by first modality, 2005–2011 cohort (adjusted to.
UK Renal Registry 17th Annual Report Figure 9.1. Median height z-scores for transplant patients
UK Renal Registry 16th Annual Report Figure Median haemoglobin for incident dialysis patients at start of dialysis treatment in 2012.
UK Renal Registry 14th Annual Report Figure 8.1. Median haemoglobin for incident dialysis patients at start of dialysis treatment in 2010.
UK Renal Registry 17th Annual Report Figure 8.1. Percentage of haemodialysis patients with phosphate within the range specified by the RA clinical audit.
~ Make a Difference ~ Become a Nephrology Nurse. Incidence (rate of occurrence) –220 per million in 1992 –334 per million in 2000 Prevalence (number of.
Diseases of the Renal System KNH 413. CKD - Renal Replacement Therapy Hemodialysis (HD) or Peritoneal Dialysis (PD) Type based on underlying kidney disease.
UKRR Annual Informatics Meeting, September 2013 Highlights from the 15 th Annual Report Rishi Pruthi Research Fellow UK Renal Registry.
© ANZDATA Registry Method and Location of Dialysis 1453 (30%) 632 (13%) 1317 (27%) 1335 (27%) Number of Patients Australia 31-Dec-96.
Asuncion Martinez Director, Nursing Care
Mary Hannon-Fletcher Micronutrient supplementation in haemodialysis patient enhances folate levels and reduces homocysteine 4th Annual Translational Medicine.
Obesity –Pharmacological treatments. Dietary management –A low energy,low fat diet is the most effective lifestyle intervention for weight loss Exercise.
UK Renal Registry 9 th Annual Report 2006 Fig 9.1 Percentage of patients with serum phosphate
Haemodialysis Vascular Access: Recent Trends From ANZDATA Dr Kevan Polkinghorne Monash Medical Centre ANZSN September 2007.
DIALYSIS Dr. Frank Edwin.
UK Renal Registry 10th Annual Report 2007 Fig 3.1 Incident rates in the countries of the UK:
UK Renal Registry 10th Annual Report 2007 Fig 8.1 Median haemoglobin for incident dialysis patients at start of dialysis treatment.
© ANZDATA Registry Method and Location of Dialysis (31%) 634 (12%) 1396 (26%) 1523 (28%) Number of Patients Australia 30-Sep-98 METHA.BRIS98.
Highlights from the Annual Report UK Renal Registry 2013 Annual Audit Meeting Dr Catriona Shaw Registrar, UK Renal Registry.
UK Renal Registry 15th Annual Report Figure 6.1. Median haemoglobin for incident dialysis patients at start of dialysis treatment in 2011.
Serum Aluminium monitoring in 16,530 dialysis patients in England and Wales: compliance with national guidelines? Udaya P Udayaraj 1, E J Lamb 2, R.Steenkamp.
Dietary Issues in Renal Complications Ulrich Wahl, Tamworth, 2010.
Prevalence and management of cardiovascular risks in renal transplant recipients Dr VS Aithal Consultant Nephrologist Swansea.
UK Renal Registry 16th Annual Report Figure Percentage of haemodialysis patients with phosphate within the range specified by the RA clinical audit.
Oxidative DNA Damage is Reduced by a Daily Micronutrient Supplement in HD Patients Dr Mary Hannon-Fletcher 2nd International Vitamin Conference 23 rd May.
UK Renal Registry 16th Annual Report Figure Median height z-scores for transplant patients
What can I eat? Renal Dietitians. Diet is an important part of your treatment, along with any medication you choose.
UK Renal Registry 10th Annual Report 2007 Fig 9.1 Annual change in percentage of dialysis patients with serum phosphate < 1.8mmol/L and ≥1.1 -≤1.8mmol/L.
UK Renal Registry 15th Annual Report Figure 7.1. Median height z-scores for transplant patients
Hyperphosphataemia in chronic kidney disease Support for education and learning for children and young people’s renal services: slide set March 2013 NICE.
Nutritional management paediatric CKD Dr. CKD – Chronic kidney disease.
KT AS A QUALITY INDICATOR OF HAEMODIALYSIS ADEQUACY: COMPARISON OF KT/V, KT ACCORDING TO THE GENDER AND BODY SURFACE AREA The dialysis dose monitored with.
Bloods – it’s all about blood.
Diseases of the Renal System
UK Renal Registry 18th Annual Report
GP Refresher Week 2015 Dietetics
When Using DOPPS Slides
Intensive Hemodialysis: Applied Clinical Practice
Fig 7.1 Median URR achieved in each renal unit
P689 THE ROLE OF NUTRITIONAL ASSESSMENT FOR SIMULTANEOUS
Diseases of the Renal System
Diseases of the Renal System
Diseases of the Renal System
Chronic kidney disease and pre-dialysis
Diseases of the Renal System
PAT: Surgical Readiness
West Midlands Renal Peer Review
Diseases of the Renal System
Diseases of the Renal System
UK Renal Registry 14th Annual Report
Fig 7.1 Median URR achieved in each centre, 2006
Diseases of the Renal System
UK Renal Registry 16th Annual Report
Stock and Flow of Haemodialysis Patients Australia
ANZDATA: Vascular Access
Stock and Flow of Haemodialysis Patients Australia
Presentation transcript:

Home Haemodialysis in Wales An Evaluation of Nutritional Needs Harriet Williams Clinical Dietitian - Renal Lead, BCU

HHD in Wales Unit% HHD 30/12/13 Renal registry data Bangor14.1 Glan Clwyd3.3 Wrexham1.6 Cardiff7.1 Swansea5.2 Total Wales6.3 Total UK4.2 Percentage of all haemodialysis patients on HHD % HHD 1 st July 2015Change 17.2 n=81+3.1% 8.3 n=84+5% 2.5 n= % 5.32 n= % 10.4 n= % 7.8 n= %

Audit All on HHD on 1 st July 2015 Data collection by Dietitians Vital data, nursing and dietetic records Dialysis hours Nutritional assessment; potassium, phosphate, fluid, nutritional status 3 months biochemistry (Differences in practice by unit)

HHD in Wales 2015 Demographics 87 patients Age years Median 54years UK HD Median 66.9 years Wales HD Median 69.3 years (registry data 2013) 2/3 Men Diabetes prevalence 24% HbA1c* 33 to 91mmol/mol (mean 58, median 59) Unit HD estimate 26.4% (2014 data) Vascular access 94% fistula (3% graft, 3% line) Transplant waiting list 34.5% *Not adjusted for Alb or Hb

% of HHD patients BMI (kg/m 2 )

HHD Vintage *Interruptions <1 year to HHD not considered as break in HHD treatment

Differences by unit Bangor (n=14) Glan Clwyd (n=7) Wrexham (n=3) Swansea (n=38) Cardiff (n=25) p-value BMI (kg/m 2 ) median Sessions / wk median Hours / wk median <0.001

Weekly dialysis hours RangeMeanMedianMode 9 to 48 hrs20 hrs15 hrs12 hrs (n=87 ) Number of hours per week, total * Prescribed dialysis hours – adherence not studied

Weekly dialysis hours Comparison of weekly dialysis hours by unit Number of patients

Dialysis regimens Regimen (weekly)N Conventional3-4.5 hours x 3 days hours x 4-7 days44 Nocturnal*5 hrs x 5-7 days 8 hrs x 4-6 days 9 hrs x 5 days 20 *Swansea and Bangor only

HHD by dialysis regimen Dialysis regimen Total Comparison of dialysis regimens by unit Number of patients Adjusted Kt/V > 1.2 = 75% (n=48)

Potassium mmol/L mmol/L>6.0mmol/L 86% (73)91% (77)9% (8) Potassium levels, total HHD, average of 3 months % of patients Dialysis regimen Potassium levels, by regimen, average of 3 months Potassium level *No hypokalaemia (<3.5mmol/L)

Potassium HD Concentrate RegimenMedian (mmol/L) K>6.0mmol/L in one month or more (of 3 months) Conventional (n=23) % 4 to 7 days (n=44) % Nocturnal (n=20)4.655% 3 patients on calcium resonium Episodes of hyperkalaemia by dialysis regimen p=0.02

Potassium No correlation with BMI, HHD vintage, hours Trend to significance with number of sessions (p=0.067)

Phosphate Achievement of phosphate target : Renal Registry data – Unit HD in Wales (2013) vs 3 months average HHD Percentage of patients Phosphate level (Target range)

Phosphate Percentage of patients Dialysis regimen *Nocturnal Addition of addiphos to dialysate (2) Sandophos orally (1) Phosphate levels by regimen, average of 3 months Phosphate level (Target range)

Phosphate RegimenMedian (mmol/L) >1.7mmol/L in one month or more Conventional (n=23) % 4 to 7 days (n=44) % Nocturnal (n=20)1.2425% Phosphate level by regimen No correlation with BMI, vintage, no. of sessions Negative correlation with hours/week (p=0.016) (Nocturnal vs conventional P=0.006)

Phosphate Binders (P<0.001) Percentage of patients Dialysis regimen Percentage of patients prescribed a phosphate binder Unit HD data from All Wales CKD-MBD audit data 2014 * excludes Cardiff and Bangor

Phosphate Binders Types of phosphate binders prescribed to those on HHD

Binder costs £103,650 yearly - 56 patients prescribed binders NICE (2013) Hyperphosphataemia in CKD. Clinical guideline 157 and costing report. RegimenNo. prescribed binder Total costAverage yearly cost / patient in group Conventional + 4 to 7 days (n=77) 54 (78.5%)£103,378£ Nocturnal (n=20)2 (10%)£272.32£13.61

Bone management HHD (n=87)Registry UHD Wales 2013 (n=1023) Adjusted calcium mmol/L <2.2mmol/L >2.2mmol/L 62% 25% 13% 73.9% 10.8% 15.4% PTH 16-72pmol/L <16pmol/L >72pmol/L Parathyroidectomy Alfacalcidol Cinacalcet 50.5% 31.2% 18.3% 16% 77% 25% 72.9% 24.4% 12.7%

Fluid (+ sodium) restriction RangeMedianMode 750 to 2000ml1000 P=0.001 Percentage of patients Dialysis regimen Percentage of patients on a fluid restriction Total 40% advised to restrict fluid intake

Nutritional status CRPNo. of patients% 0 – 52226% % 31 – 10078% >10056% Alb < 35g/L26 (30%) n=87 Percentage of HHD patients with Alb< 35g/L CRP levels amongst HHD patients

Water soluble vitamins Number of patients prescribed vitamins B and C Number of patients prescribed vitamins by dialysis regimen

Current Dietetic Input...within one month of starting dialysis, stable patients reviewed at a minimum of 6 monthly. Frequency of review will vary dependant on the stability of diet related electrolytes and nutritional status. Reviews may need to increase to monthly in those with unstable biochemistry or significantly reduced appetite, intake or flesh weight loss.(Renal Association 2010). UnitNDietetic assessment within past 6 months (%) p=0.002 Bangor1464 Glan Clwyd729 Wrexham3100 Cardiff2576 Swansea3832 Total4552% BCU data % all unit HD assessed within past 6/12

Dietetic input in all seen over past 12 months number % of patients Assessment3136% Monitoring5057% K Lowering2124% P04 Lowering2630% Nutrition support – energy1517% Nutrition support – protein1821% Supplements1315% Salt67% Fluid1011% K increasing58% PO4 Increasing58% Micronutrients33% Weight reducing5 6% Diabetes advice1 1% Fibre3 3% Healthy eating1 1% Other1921% 25% of Nocturnal

Summary Nutrition related issues remain in the HHD population Differing HHD practices between units may influence nutritional needs Hyperkalaemia and the need for fluid restriction are still present but reduced with greater frequency and to a greater extent nocturnal HD Nocturnal HD offers advantages – phosphate control, reduced binder prescription, freedom from fluid restriction Otherwise hyperphosphatemia remains a significant issue Protein and micronutrient intake need attention Current input – half receive the minimum unit HD standard

Conclusion Dietetic input remains an integral part of the care of people choosing haemodialysis at home A need to ensure equitable services – in unit, at home and across Wales